GCG and type 2 diabetes mellitus: In T2D, therapeutic options, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, incretin-based drugs, and GLP-1 analogues, target β-cell function, but not all patients are responsive and approximately 50% ultimately require daily insulin injections due to β-cell exhaustion and death (149).